Top

Reactions Weekly

Published in:

01-04-2024 | Alemtuzumab | Case report

Alemtuzumab

Lack of efficacy

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Lapucci C, et al. A real life, multicenter, observational study to evaluate safety and efficacy of the switch from alemtuzumab to ocrelizumab in MS patient with evidence of disease activity after two alemtuzumab courses: the italian experience. Multiple Sclerosis Journal 29 (Suppl. 3): 441-442 abstr. P466, Oct 2023. Available from: URL: https://dx.doi.org/10.1177/1352458523 [abstract]

Title: Alemtuzumab
Lack of efficacy
Publication date: 01-04-2024
Publisher: Springer International Publishing
Keywords: Alemtuzumab
Alemtuzumab
Multiple Sclerosis
Human Alphaherpesvirus 3
Ocrelizumab
Ocrelizumab
Herpes Virus
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-55406-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Alemtuzumab

Lack of efficacy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Difluprednate/mycophenolate mofetil/prednisone

Nirmatrelvir+ritonavir

Daratumumab

Enoxaparin-sodium/rifampicin/warfarin

Prednisolone

Lomustine